SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

UltiPace™ Pacing Lead

Robust Stylet-Driven Leads for Left Bundle Branch Area Pacing

Pioneering Innovation in LBBAP

Experience the innovation of the UltiPace Pacing Lead, Abbott's latest breakthrough, and the only approved stylet-driven lead for left bundle branch area pacing (LBBAP) with a robust distal lead tip design.* Engineered for superior performance in the pursuit of continuous innovation.1

UltiPace cross section

Proven Design Evolved

UltiPace cross section

vs. Tendril™ STS1

3X

Increase in abrasion resistance

3.5X

Increase in lead crush resistance

vs. Tendril MRI™ 1

2.2X

Increase in abrasion resistance

2.6X

Increase in lead crush resistance

Demonstrated LBBAP Success and Safety


Composite
success
rate2**

93% circle

of patients not experiencing
LBBAP-related adverse effects at  6 months post-implant.2

99.5% circle

Resistant to Distal Fatigue Failure

UltiPace Pacing Leads have a robust distal lead tip without a flexible zone that helps reduce stress on the conductors and the chance for distal fatigue failure compared to competitive leads.3

Ulipace pacing leads

Zero Helix Retraction

The Helix Locking Tool is a proven solution to lock an extended helix during tissue burrowing without retraction.3

UltiPace cross section

The Helix Locking Tool aids with lead fixation by providing control over the extension and retraction of the helix.

The Helix Locking Tool helps deploy the active fixation helix and hold it in place

Improved Torque Transmission with Fewer Rotations

 

Improvement in torsional stiffness when using UltiPace Pacing Leads compared to LBBAP-approved lumenless pacing leads.3

94% circle

Torque being applied to UltiPace Pacing Lead body in LBBAP procedure.

Ensuring optimal slack during stylet retraction is key to preventing complications


Continuous Unipolar Pacing and Impedance Monitoring

Provides the user with uninterrupted feedback to help achieve optimal results.4

References

*Robust distal lead tip without a flexible zone in distal 14.5 mm, CE and FDA Approval for LBBAP.
**Composite success rate of acceptable capture thresholds and sense amplitudes for LBBAP at 6 months post-implant.

  1. Abbott. Data on File. Item: 91010074 Ver A.
  2. Abbott. Data on File.
  3. Abbott. Data on File, Engineering Technical Report. Item: 90994484 Ver D.
  4. Burri, H., Jastrzebski, M., Cano, O., Curila, K., Pooter, J. de, Huang, W., Israel, C., Joza, J., Romero, J., Vernooy, K., Vijayaraman, P., Whinnett, Z., & Zanon, F. (2023). EHRA clinical consensus statement on conduction system pacing implantation: Executive summary. endorsed by the Asia-Pacific Heart Rhythm Society (APHRS), Canadian heart rhythm society (CHRS) and Latin-American heart rhythm society (LAHRS). Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. https:// pubmed.ncbi.nlm.nih.gov/37061850/

Indications:

The UltiPace™ leads are indicated for use in combination with a compatible pacemaker, implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT ‑P/CRT ‑D) device to provide sensing and pacing for the management of chronic symptomatic bradycardia and various atrioventricular conduction abnormalities in patients who experience syncope, presyncope, fatigue, or disorientation due to arrhythmia/bradycardia, or any combination of these symptoms. The UltiPace leads are implanted transvenously in either the right atrium, the right ventricle or the left bundle branch area.

For indications for the pacing system, please refer to the applicable pulse generator manual.

MAT-2411896 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0